The delayed-release combination of doxylamine and pyridoxine (Diclegis®/Diclectin ®) for the treatment of nausea and vomiting of pregnancy

Svetlana Madjunkova, Caroline Maltepe, Gideon Koren, Svetlana Madjunkova, Caroline Maltepe, Gideon Koren

Abstract

Nausea and vomiting of pregnancy (NVP) affects up to 85 % of all pregnancies. Effective treatment can greatly improve a woman's quality of life, reduce the risk for maternal and fetal complications, and reduce healthcare costs. Unfortunately, many women receive either no pharmacological treatment or are recommended therapies for which fetal safety and efficacy have not been established. First-line treatment of NVP, as recommended by several leading healthcare and professional organizations, is the combination of doxylamine and pyridoxine. This combination, formulated as a 10 mg/10 mg delayed-release tablet, was approved by the US Food and Drug Administration (FDA) for the treatment of NVP in April 2013 under the brand name Diclegis(®), and has been on the Canadian market since 1979, currently under the brand name Diclectin(®). The efficacy of Diclegis(®)/Diclectin(®) has been demonstrated in several clinical trials, and, more importantly, studies on more than 200,000 women exposed to doxylamine and pyridoxine in the first trimester of pregnancy have demonstrated no increased fetal risk for congenital malformations and other adverse pregnancy outcomes. The present review aims to present the scientific evidence on the effectiveness and fetal safety of Diclegis(®)/Diclectin(®) for the treatment of NVP to justify its use as first-line treatment for NVP.

Figures

Fig. 1
Fig. 1
Chemical structure of Diclegis®/Diclectin® [10 mg doxylamine succinate/10 mg pyridoxine hydrochloride (HCl)]. a Doxylamine succinate is classified as an antihistamine. The chemical name for doxylamine succinate is ethanamine, N,N-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]-butanedioate (1:1) 2-[α-[2-(dimethylamino)ethoxy]-α-methylbenzyl] pyridine succinate (1:1). The empirical formula is C17H22N2O · C4H6O4 and the molecular mass is 388.46 g/mol. It is very soluble in water and alcohol, readily soluble in chloroform, and slightly soluble in ether and benzene. b Pyridoxine HCl is vitamin B6. Its chemical name is 5-hydroxy-6-methyl-3,4-pyridine dimethanol hydrochloride. The empirical formula C8H11NO3 · HCl and molecular mass is 205.64 g/mol. Pyridoxine HCl is readily soluble in water, slightly soluble in alcohol, and insoluble in ether

References

    1. Lacroix R, Eason E, Melzack R. Nausea and vomiting during pregnancy: a prospective study of its frequency, intensity, and patterns of change. Am J Obstet Gynecol. 2000;182(4):931–7.
    1. Clark SM, Costantine MM, Hankins GD. Review of NVP and HG and early pharmacotherapeutic intervention. Obstet Gynecol Int. 2012;252676(10):24.
    1. APGO. Nausea and vomiting of pregnancy. APGO Educational series on women’s health issues. Boston: Jespersen & Associates, LLC; 2013.
    1. Goodwin TM. Hyperemesis gravidarum. Obstet Gynecol Clin North Am. 2008;35(3):401–417. doi: 10.1016/j.ogc.2008.04.002.
    1. Czeizel AE, Dudas I, Fritz G, Tecsoi A, Hanck A, Kunovits G. The effect of periconceptional multivitamin-mineral supplementation on vertigo, nausea and vomiting in the first trimester of pregnancy. Arch Gynecol Obstet. 1992;251(4):181–185. doi: 10.1007/BF02718384.
    1. Koren G, Maltepe C. Pre-emptive therapy for severe nausea and vomiting of pregnancy and hyperemesis gravidarum. J Obstet Gynaecol. 2004;24(5):530–533. doi: 10.1080/01443610410001722581.
    1. Bottomley C, Bourne T. Management strategies for hyperemesis. Best Pract Res Clin Obstet Gynaecol. 2009;23(4):549–564. doi: 10.1016/j.bpobgyn.2008.12.012.
    1. Verberg MF, Gillott DJ, Al-Fardan N, Grudzinskas JG. Hyperemesis gravidarum, a literature review. Hum Reprod Update. 2005;11(5):527–539. doi: 10.1093/humupd/dmi021.
    1. Jueckstock JK, Kaestner R, Mylonas I. Managing hyperemesis gravidarum: a multimodal challenge. BMC Med. 2010;8(46):1741–7015.
    1. Koch KL. Gastrointestinal factors in nausea and vomiting of pregnancy. Am J Obstet Gynecol. 2002;186(5 Suppl Understanding):S198–203.
    1. Koch KL, Frissora CL. Nausea and vomiting during pregnancy. Gastroenterol Clin North Am. 2003;32(1):201–234. doi: 10.1016/S0889-8553(02)00070-5.
    1. Nguyen P, Einarson A. Managing nausea and vomiting of pregnancy with pharmacological and nonpharmacological treatments. Women’s health (London, England). 2006;2(5):753–60. doi:10.2217/17455057.2.5.753.
    1. Gill SK, Maltepe C, Koren G. The effect of heartburn and acid reflux on the severity of nausea and vomiting of pregnancy. Can J Gastroenterol. 2009;23(4):270–272.
    1. Golberg D, Szilagyi A, Graves L. Hyperemesis gravidarum and Helicobacter pylori infection: a systematic review. Obstet Gynecol. 2007;110(3):695–703. doi: 10.1097/01.AOG.0000278571.93861.26.
    1. Sandven I, Abdelnoor M, Nesheim BI, Melby KK. Helicobacter pylori infection and hyperemesis gravidarum: a systematic review and meta-analysis of case–control studies. Acta Obstet Gynecol Scand. 2009;88(11):1190–1200. doi: 10.3109/00016340903284927.
    1. Vikanes AV, Stoer NC, Gunnes N, Grjibovski AM, Samuelsen SO, Magnus P, et al. Helicobacter pylori infection and severe hyperemesis gravidarum among immigrant women in Norway: a case–control study. Eur J Obstet Gynecol Reprod Biol. 2013;167(1):41–46. doi: 10.1016/j.ejogrb.2012.11.007.
    1. Sherman PW, Flaxman SM. Nausea and vomiting of pregnancy in an evolutionary perspective. Am J Obstet Gynecol. 2002;186(5 Suppl Understanding):S190–7.
    1. Fejzo MS, Macgibbon KW, Romero R, Goodwin TM, Mullin PM. Recurrence risk of hyperemesis gravidarum. J Midwifery Womens Health. 2011;56(2):132–136. doi: 10.1111/j.1542-2011.2010.00019.x.
    1. Fejzo MS, Ingles SA, Wilson M, Wang W, MacGibbon K, Romero R, et al. High prevalence of severe nausea and vomiting of pregnancy and hyperemesis gravidarum among relatives of affected individuals. Eur J Obstet Gynecol Reprod Biol. 2008;141(1):13–17. doi: 10.1016/j.ejogrb.2008.07.003.
    1. Attard CL, Kohli MA, Coleman S, Bradley C, Hux M, Atanackovic G, et al. The burden of illness of severe nausea and vomiting of pregnancy in the United States. Am J Obstet Gynecol. 2002;186(5 Suppl Understanding):S220–7.
    1. Lacasse A, Rey E, Ferreira E, Morin C, Berard A. Nausea and vomiting of pregnancy: what about quality of life? Bjog. 2008;115(12):1484–1493. doi: 10.1111/j.1471-0528.2008.01891.x.
    1. Miller F. Nausea and vomiting in pregnancy: the problem of perception—is it really a disease? Am J Obstet Gynecol. 2002;186(5 Suppl Understanding):S182–3.
    1. Mazzotta P, Stewart DE, Koren G, Magee LA. Factors associated with elective termination of pregnancy among Canadian and American women with nausea and vomiting of pregnancy. J Psychosom Obstet Gynaecol. 2001;22(1):7–12. doi: 10.3109/01674820109049946.
    1. Piwko C, Ungar WJ, Einarson TR, Wolpin J, Koren G. The weekly cost of nausea and vomiting of pregnancy for women calling the Toronto Motherisk Program. Curr Med Res Opin. 2007;23(4):833–40.
    1. Piwko C, Koren G, Babashov V, Vicente C, Einarson TR. Economic burden of nausea and vomiting of pregnancy in the USA. J Popul Ther Clin Pharmacol. 2013;20(2):10.
    1. Weigel RM, Weigel MM. Nausea and vomiting of early pregnancy and pregnancy outcome. A meta-analytical review. Br J Obstet Gynaecol. 1989;96(11):1312–1318. doi: 10.1111/j.1471-0528.1989.tb03229.x.
    1. Nulman I, Rovet J, Barrera M, Knittel-Keren D, Feldman BM, Koren G. Long-term neurodevelopment of children exposed to maternal nausea and vomiting of pregnancy and Diclectin. J Pediatr. 2009;155(1):45–50. doi: 10.1016/j.jpeds.2009.02.005.
    1. Veenendaal MV, van Abeelen AF, Painter RC, van der Post JA, Roseboom TJ. Consequences of hyperemesis gravidarum for offspring: a systematic review and meta-analysis. BJOG. 2011;118(11):1302–1313. doi: 10.1111/j.1471-0528.2011.03023.x.
    1. van Oppenraaij RH, Jauniaux E, Christiansen OB, Horcajadas JA, Farquharson RG, Exalto N. Predicting adverse obstetric outcome after early pregnancy events and complications: a review. Hum Reprod Update. 2009;15(4):409–421. doi: 10.1093/humupd/dmp009.
    1. Roseboom TJ, Ravelli AC, van der Post JA, Painter RC. Maternal characteristics largely explain poor pregnancy outcome after hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol. 2011;156(1):56–59. doi: 10.1016/j.ejogrb.2011.01.010.
    1. Einarson A, Maltepe C, Boskovic R, Koren G. Treatment of nausea and vomiting in pregnancy: an updated algorithm. Can Fam Physician. 2007;53(12):2109–2111.
    1. Jewell D, Young G. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev. 2003;4:CD000145.
    1. Scorza K, Williams A, Phillips JD, Shaw J. Evaluation of nausea and vomiting. Am Fam Physician. 2007;76(1):76–84.
    1. Gill SK, Einarson A. The safety of drugs for the treatment of nausea and vomiting of pregnancy. Expert Opin Drug Saf. 2007;6(6):685–694. doi: 10.1517/14740338.6.6.685.
    1. Brent RL. Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen–litigen. Reprod Toxicol. 1995;9(4):337–349. doi: 10.1016/0890-6238(95)00020-B.
    1. Einarson TR, Leeder JS, Koren G. A method for meta-analysis of epidemiological studies. Drug Intell Clin Pharm. 1988;22(10):813–824.
    1. McKeigue PM, Lamm SH, Linn S, Kutcher JS. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. Teratology. 1994;50(1):27–37. doi: 10.1002/tera.1420500105.
    1. Magee LA, Mazzotta P, Koren G. Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol. 2002;186(5 Suppl Understanding):S256–61.
    1. Koren G, Clark S, Hankins GD, Caritis SN, Miodovnik M, Umans JG, et al. Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. Am J Obstet Gynecol. 2010;203(6):16. doi: 10.1016/j.ajog.2010.07.030.
    1. ACOG. ACOG (American College of Obstetrics and Gynecology) practice bulletin: nausea and vomiting of pregnancy. Obstet Gynecol. 2004;103(4):803–14.
    1. SOGC. Clinical practice guidelines. The management of nausea and vomiting of pregnancy. J Obstet Gynaecol Can. 2002;24(10):817–23.
    1. MothertoBaby. Nausea and vomiting. In: Maternal medical conditions fact sheets. . 2013.
    1. . Accessed: October 01, 2013.
    1. Brent R. Bendectin and birth defects: hopefully, the final chapter. Birth Defects Res A Clin Mol Teratol. 2003;67(2):79–87. doi: 10.1002/bdra.10021.
    1. Kutcher JS, Engle A, Firth J, Lamm SH. Bendectin and birth defects. II: ecological analyses. Birth Defects Res A Clin Mol Teratol. 2003;67(2):88–97. doi: 10.1002/bdra.10034.
    1. Bendectin Peer Review Report 1975. Overall summary of 8-way Bendectin Study (unpublished study from the FDA databan DESI-10598). FDA1975 Contract No.: DESI 10598.
    1. Ornstein M, Einarson A, Koren G. Bendectin/Diclectin for morning sickness: a Canadian follow-up of an American tragedy. Reprod Toxicol. 1995;9(1):1–6.
    1. . Accessed: October 01, 2013.
    1. Neutel CI, Johansen HL. Measuring drug effectiveness by default: the case of Bendectin. Can J Public Health. 1995;86(1):66–70.
    1. Martindale: The complete drug reference. 37th ed. Database on the internet. London: Pharmaceutical Press; 2011.
    1. Ottawa TCPA. Compendium of pharmaceuticals and specialties. Ottawa, ON. 2013. .
    1. Vutyavanich T, Wongtra-ngan S, Ruangsri R. Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 1995;173(3 Pt 1):881–884. doi: 10.1016/0002-9378(95)90359-3.
    1. Sahakian V, Rouse D, Sipes S, Rose N, Niebyl J. Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: a randomized, double-blind placebo-controlled study. Obstet Gynecol. 1991;78(1):33–36.
    1. Serafin WE, Babe KS. H1-receptor antagonists. In: Gilman AG, Hardman JG, Limbird LE, et al., editors. The pharmacological basis of therapeutics. New York: McGraw-Hill Companies; 1996. p. 586–692.
    1. Koren G. Treating morning sickness PRN? Can Fam Physician. 2013;59(2):150–151.
    1. Tani AS. Antihistamines. In: Olson K, editor. Poisoning & drug overdose. Norwalk: Appletin&Lange; 1998. pp. 78–79.
    1. Ganes DA, Midha KK. Identification in in vivo acetylation pathway for N-dealkylated metabolites of doxylamine in humans. Xenobiotica. 1987;17(8):993–999. doi: 10.3109/00498258709044198.
    1. Gregory JF., 3rd Bioavailability of vitamin B-6. Eur J Clin Nutr. 1997;51(1):S43–S48.
    1. Mukherjee T, Hanes J, Tews I, Ealick SE, Begley TP. Pyridoxal phosphate: biosynthesis and catabolism. Biochim Biophys Acta. 2011;11(96):8.
    1. di Salvo ML, Safo MK, Contestabile R. Biomedical aspects of pyridoxal 5’-phosphate availability. Front Biosci. 2012;4:897–913. doi: 10.2741/E428.
    1. Duchesnay Inc. Diclectin product monograph. Blainville, Quebec, Canada. 2013. p. 1–24.
    1. Nulman I, Koren G. Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrocholoride (Diclectin) and oral solutions of these drugs in healthy women of childbearing age. Can J Clin Pharmacol. 2009;16(3):29.
    1. Gill SK, Garcia-Bournissen F, Koren G. Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin) Ther Drug Monit. 2011;33(1):115–119. doi: 10.1097/FTD.0b013e3181ff8bc5.
    1. Koren G, Vranderick M, Gill SK, Macleod S. Sex differences in the pharmacokinetics and bioequivalence of the delayed-release combination of doxylamine succinate–pyridoxine hydrochloride; implications for pharmacotherapy in pregnancy. J Clin Pharmacol. 2013;30(10):184.
    1. Matok I, Clark S, Caritis S, Miodovnik M, Umans J, Hankins G, et al. Comparing the pharmacokinetics of doxylamine/pyridoxine delayed-release combination in nonpregnant women of reproductive age and women in the first trimester of pregnancy. J Clin Pharmacol. 2013;53(3):334–338. doi: 10.1177/0091270012445207.
    1. Rowland JM, Slikker W, Jr, Holder CL, Denton R, Prahalada S, Young JF, et al. Pharmacokinetics of doxylamine given as Bendectin in the pregnant monkey and baboon. Reprod Toxicol. 1989;3(3):197–202. doi: 10.1016/0890-6238(89)90007-5.
    1. Geiger CJ, Fahrenbach DM, Healey FJ. Bendectin in the treatment of nausea and vomiting in pregnancy. Obstet Gynecol. 1959;14:688–690.
    1. McGuinness BW, Binns DT. ‘Debendox’ in pregnancy sickness. J R Coll Gen Pract. 1971;21(109):500–503.
    1. Wheatley D. Treatment of pregnancy sickness. Br J Obstet Gynaecol. 1977;84(6):444–447. doi: 10.1111/j.1471-0528.1977.tb12620.x.
    1. Bishai R, Mazzotta P, Atanackovic G, Levichek Z, Pole M, Magee LA, et al. Critical appraisal of drug therapy for nausea and vomiting of pregnancy: II. Efficacy and safety of Diclectin (doxylamine-B6) Can J Clin Pharmacol. 2000;7(3):138–143.
    1. Ebrahimi N, Maltepe C, Bournissen FG, Koren G. Nausea and vomiting of pregnancy: using the 24-hour Pregnancy-Unique Quantification of Emesis (PUQE-24) scale. J Obstet Gynaecol Can. 2009;31(9):803–807.
    1. Neutel I, Johansen HI. Variation in rates hospitalization for excessive vomiting in pregnancy by Bendectin/Diclectin use in Canada. Nausea and vomiting of pregnancy. State of the art. Toronto: The Motherisk Program; 2000. p. 54–9.
    1. Gadsby R, Barnie-Adshead AM, Jagger C. A prospective study of nausea and vomiting during pregnancy. Br J Gen Pract. 1993;43(371):245–248.
    1. Boskovic R, Einarson A, Maltepe C, Wolpin J, Koren G. Diclectin therapy for nausea and vomiting of pregnancy: effects of optimal dosing. J Obstet Gynaecol Can. 2003;25(10):830–833.
    1. Atanackovic G, Navioz Y, Moretti ME, Koren G. The safety of higher than standard dose of doxylamine–pyridoxine (Diclectin) for nausea and vomiting of pregnancy. J Clin Pharmacol. 2001;41(8):842–845. doi: 10.1177/00912700122010735.
    1. Costantine MM, Matok I, Chiossi G, Clark S, Miodovnik M, Umans JG, et al. Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy. Ther Drug Monit. 2012;34(5):569–573. doi: 10.1097/FTD.0b013e31826e7997.
    1. Maltepe C, Koren G. Preemptive treatment of nausea and vomiting of pregnancy: results of a randomized controlled trial. Obstet Gynecol Int. 2013;2013:809787. doi: 10.1155/2013/809787.
    1. Brent R. Medical, social, and legal implications of treating nausea and vomiting of pregnancy. Am J Obstet Gynecol. 2002;186(5 Suppl Understanding):S262–6.
    1. Koren G. The return to the USA of doxylamine-pyridoxine delayed release combination (Diclegis(R)) for morning sickness–a new morning for American women. J Popul Ther Clin Pharmacol. 2013;20(2):14.
    1. Gibson JP, Staples RE, Larson EJ, Kuhn WL, Holtkamp DE, Newberne JW. Teratology and reproduction studies with an antinauseant. Toxicol Appl Pharmacol. 1968;13(3):439–447. doi: 10.1016/0041-008X(68)90120-8.
    1. Hendrickx AG, Cukierski M, Prahalada S, Janos G, Rowland J. Evaluation of Bendectin embryotoxicity in nonhuman primates: I. Ventricular septal defects in prenatal macaques and baboon. Teratology. 1985;32(2):179–189. doi: 10.1002/tera.1420320205.
    1. Briggs GG, Roger K. Freemen, Yaffe SJ. Drugs in pregnancy and lactation. 9th ed. Philadelphia: Lippincott Williams&Wilkins; 2011.
    1. Reprotox® database [electronic version] [homepage on the Internet] [database on the Internet]. 2013. Accessed: October 03, 2013.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner